Skip to main content

The LLS Blog

Read about survivors, research, fundraising and advocacy.

Meet Three Women in Science Championing Myeloma Cures and Care

Annamaria Gulla, MD, Dana-Farber Cancer Institute, is an LLS Career Development Program Fellow. With support from LLS, Dr. Gulla is working to improve outcomes for multiple myeloma patients through the power of immunotherapy. Immunotherapy – harnessing the immune system to fight cancer – has become a mainstay in cancer treatment. One promising approach centers on the evidence that cancer cells dying from specific treatment can be recognized by the patient’s own immune system, triggering an immune response against the disease. Dr. Gulla aims to characterize the molecular mechanisms behind this process – called immunogenic cell death – in multiple myeloma.

Meet The Researcher: Dr. Rayne Rouce

To commemorate Black History Month, LLS is highlighting exceptional clinicians and healthcare professionals throughout the month of February. Dr. Rayne Rouce is a physician at Texas Children's Cancer Center where she is a member of the Leukemia/Lymphoma/Bone Marrow Transplant/Stem Cell Transplant Program. Dr. Rouce is board certified in pediatrics and pediatric hematology/oncology by the American Board of Pediatrics.

Take Part in the Raise Hope, End Cancer Fundraiser with Walgreens

Walgreens, The Leukemia & Lymphoma Society (LLS), and Susan G. Komen (Komen) are collaborating to raise funds to enable new research in breast and blood cancers and expand access, treatment, and support services for those living with these diseases. In 2019, Walgreens pledged to contribute more than $25 million to LLS and Komen collectively over the next five years to improve the health and well-being of people living with cancer nationwide. But we can’t do this alone.

Practicing Self-Advocacy During My PTCL Journey

The LLS Blog invites Aaron, who was diagnosed with peripheral T-cell lymphoma (PTCL), to share his reflections on becoming a self-advocate throughout his cancer experience. Read his powerful first-hand account

Precision Medicine and Combination Therapies #ASH20

The more we learn more about the underlying mutations that drive cancer the better we get at more precisely hitting those targets with specialized, less toxic treatments. We now understand that a one-size-fits all approach to treating cancer is ineffective for many patients. As The 62nd American Society of Hematology (ASH) annual Meeting ends, let’s take a look at results from studies of targeted therapies that work by interfering with the altered genes that cause cancer cells to grow and spread. Much of the work stems from research supported by LLS.

Older Posts